Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 19.1 of its flagship scientific informatics platform D360. D360 v19.1 expands the platform’s capabilities for biologists and biologics scientists, deepens support for small molecule chemistry, and provides workflow enhancements based on community feedback. This latest version of D360 takes its name from its calendar release date; this is the first new release in 2019.
The role of drug discovery scientists has expanded and evolved during the past few years due to the dramatic increase in research into new therapeutic modalities. Rapid scientific advances have resulted in a range of new therapies; peptides, oligonucleotides, antibodies and other biologic therapeutics. There were a record-breaking 17 new biologics approved by the US Food and Drug Administration in 2018. Certara’s roadmap for D360 aligns to those growth areas, adding analytic capabilities for both small molecules and biologics.
“Based on feedback from the discovery research community, we believe that D360 is the premier data delivery and analytics application for improving go/no-go decisions in drug discovery. D360 offers users superior data access, analytics, visualization and collaboration tools in a single package. We now have more than 6,000 active users across the small molecule, biologics and preclinical data domains at pharmaceutical and biotechnology companies of all sizes,” said David Lowis, D. Phil., senior director of D360 at Certara.
“As the market evolves, we collaborate closely with our customers to ensure that D360 meets their current and future needs. We regularly consult with scientists through our international D360 User Group Meetings. Five of the top 10 pharmaceutical companies are active members of the D360 Customer Steering Committee, helping to drive the product’s strategic direction. As a result of customer requests, this is the second consecutive D360 release to offer expanded biologics capabilities, providing additional analysis tools to drive oligonucleotide, peptide, and monoclonal antibody research,” said Dr. Lowis.